Search results for " liver disease"

showing 10 items of 559 documents

Hyperferritinemia is a risk factor for steatosis in chronic liver disease.

2009

AIM: To investigate the relationship between ferritin and steatosis in patients with chronically abnormal liver function tests (LFTs) and high ferritin level. METHODS: One hundred and twenty-four consecutive patients with hyperferritinemia (male > 300 ng/mL, female > 200 ng/mL) were evaluated; clinical, biochemical and serological data, iron status parameters, HFE gene mutations and homeostasis model assessment score were obtained. Steatosis was graded by ultrasound as absent or present. Histology was available in 53 patients only. RESULTS: Mean level of ferritin was 881 ± 77 ng/mL in men and 549 ± 82 ng/mL in women. The diagnosis was chronic hepatitis C in 53 (42.7%), non-alcoholic fatty l…

MalePathologymedicine.medical_specialtyHyperferritinemia chronic liver disease.Chronic liver diseaseGastroenterologyLiver Function TestsRisk FactorsInternal medicinemedicineHumansmedicine.diagnostic_testbiologybusiness.industryLiver DiseasesFatty liverGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseFerritinFatty LiverBrief ArticlesLiver biopsyHereditary hemochromatosisChronic DiseaseFerritinsMutationbiology.proteinAbnormal Liver Function TestFemaleSteatosisSteatohepatitisbusinessWorld journal of gastroenterology
researchProduct

Evaluation by Ultrasound of Abdominal Lymphadenopathy in Chronic Hepatitis C

1999

Objective: Abdominal ultrasound has shown a frequent association between abdominal lymphadenopathy (LA) and chronic liver disease, but contradictory data have been reported on its relationship with the main parameters of hepatic function. The aim of this study was to correlate the prevalence of LA in patients who were chronic hepatitis-anti-hepatitis C virus positive prospectively followed-up over the last 3 years and its relationship with biochemical and histological data. Methods: 136 RIBA II confirmed positive patients with ALT levels >2N were included. None of these had been or was at the time of study on interferon treatment. Ultrasound was performed using a Toshiba SSA 240 A apparatus…

MalePathologymedicine.medical_specialtyTime FactorsSettore MED/09 - Medicina InternaTime FactorBiopsyHepatitis C virusmedicine.disease_causeChronic liver diseaseGastroenterologyFollow-Up StudieLiver diseaseLiver Function TestsInternal medicineBiopsyPrevalencemedicineHumansLymphatic DiseasesUltrasonographyHepatologymedicine.diagnostic_testLiver Function TestReverse Transcriptase Polymerase Chain Reactionbusiness.industryGastroenterologyCase-control studyClinical Enzyme TestHepatitis CClinical Enzyme TestsHepatitis C ChronicMiddle Agedmedicine.diseasemedicine.anatomical_structureLiverCase-Control StudiesAbdomenFemaleLymphatic DiseaseCase-Control StudieLiver function testsbusinessFollow-Up StudiesHumanAmerican Journal of Gastroenterology
researchProduct

Non-alcoholic fatty liver disease and the development of nephrolithiasis: A cohort study.

2017

Background Non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation or precursor of metabolic syndrome, may increase nephrolithiasis, a renal manifestation of insulin resistance, but the prospective association between NAFLD and incident nephrolithiasis has not been evaluated. We examined the association of NAFLD with the development of nephrolithiasis in a large cohort of Korean men and women. Methods We performed a cohort study of 208,578 Korean adults who underwent a health checkup examination between January 2002 and December 2014 and were followed-up annually or biennially through December 2014. NAFLD was defined as the presence of fatty liver in the absence of excessive alco…

MalePhysiology030232 urology & nephrologylcsh:MedicineBlood PressureGastroenterologyVascular MedicineBody Mass IndexCohort Studies0302 clinical medicineEndocrinologyNon-alcoholic Fatty Liver DiseaseMedicine and Health Scienceslcsh:ScienceMultidisciplinaryAlcohol ConsumptionIncidence (epidemiology)Liver DiseasesHazard ratioFatty liverMiddle AgedChemistryPhysiological ParametersResearch DesignHypertensionPhysical Sciences030211 gastroenterology & hepatologyFemaleCohort studyResearch ArticleAdultmedicine.medical_specialtyEndocrine DisordersGastroenterology and HepatologyNephrolithiasisResearch and Analysis Methods03 medical and health sciencesInsulin resistanceInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansNutritionEndocrine Physiologybusiness.industrylcsh:RBody WeightChemical Compoundsnutritional and metabolic diseasesBiology and Life Sciencesmedicine.diseasedigestive system diseasesDietUric AcidFatty LiverMetabolic Disorderslcsh:QMetabolic syndromeInsulin ResistancebusinessBody mass indexAcidsPloS one
researchProduct

Adult to Adult Living Donor Liver Transplantation in Recipients with Low MELD: A Strategy Intended to Overcome Donor Shortage

2020

Recent series have demonstrated advantages of living donor over deceased donor liver transplantation, with particular benefit for those with low model for end-stage liver disease score. The logic underlying the transplantation of patients before they become too sick is intuitive. It reduces mortality and drop outs from the waiting list and makes transplant surgery less demanding. Those principles have to be balanced with donor safety and transplant benefit for the recipient avoiding early, futile transplantation. The authors report a case of adult to adult right lobe living donor liver transplantation performed for a recipient affected by primary biliary cirrhosis with MELD score of 15, in …

MalePhysiologymedicine.medical_treatmentLiver transplantationSeverity of Illness IndexLiver diseasePostoperative Complications0302 clinical medicinePrimary biliary cirrhosisTransplant surgeryLiving DonorsLiver Transplantation.Liver resectionLiver Cirrhosis BiliaryGastroenterologyCone-Beam Computed TomographyMiddle AgedTreatment Outcomesurgical procedures operativeItalyLiver030220 oncology & carcinogenesisFemaleRisk Adjustment030211 gastroenterology & hepatologyLiving donor liver transplantationHumanAdultmedicine.medical_specialtyTissue and Organ ProcurementClinical Decision-MakingTime-to-TreatmentEnd Stage Liver Disease03 medical and health sciencesInternal medicineSeverity of illnessmedicineHepatectomyHumansIntensive care medicineLiver transplantationbusiness.industryLiving donor liver transplantationHepatologymedicine.diseasePleural EffusionTransplantationSurgeryPostoperative Complicationbusiness
researchProduct

Under-prescription of statins in patients with non-alcoholic fatty liver disease

2017

Abstract Background and Aim Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with high cardiovascular risk. Management of dyslipidaemia plays a pivotal role in the prevention of CV events and statins have proved to be safe in these patients. However, in everyday clinical practice statin prescription is sometimes limited because of the concern of physicians about side-effects. The aim of the study was to investigate if the presence of NAFLD affects the prescription of lipid-lowering treatment in a large series of patients with cardio-metabolic disorders. Methods and Results Cardiovascular risk and LDL-C targets were defined according to ESC/EAS Guidelines in 605 conse…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Disease030204 cardiovascular system & hematologyEndocrinology0302 clinical medicineDrug PrescriptionNon-alcoholic Fatty Liver DiseaseRisk FactorsCardiovascular DiseaseNutrition and DieteticPractice Patterns Physicians'Nutrition and Dieteticsmedicine.diagnostic_testFatty liverMiddle AgedDiabetes and MetabolismCardiovascular DiseasesPractice Guidelines as TopicCohortUnder-prescriptionFemalelipids (amino acids peptides and proteins)030211 gastroenterology & hepatologyGuideline AdherenceCardiology and Cardiovascular MedicineHumanAdultCardiovascular risk; Non-alcoholic fatty liver disease; Statins; Under-prescription; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyStatinmedicine.drug_classContext (language use)Health Services MisuseDrug Prescriptions03 medical and health sciencesInternal medicinemedicineHumansMedical prescriptionAgedDyslipidemiasCross-Sectional Studiebusiness.industryRisk FactorStatinsStatinnutritional and metabolic diseasesNon alcoholicBiomarkerCholesterol LDLCardiovascular riskmedicine.diseaseCross-Sectional StudiesDyslipidemiaPhysical therapyHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsLipid profilebusinessBiomarkersNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Nonalcoholic fatty liver and metabolic syndrome in Italy: Results from a multicentric study of the Italian Arteriosclerosis society

2013

Nonalcoholic fatty liver disease (NAFLD) is associated with all the components of metabolic syndrome (MS) and might to be considered an additional component of MS itself. The Italian Society for the Study of Atherosclerosis (SISA) in 2005 started a research project aimed to study the NAFLD, using ultrasound (US), in nondiabetic MS subjects matching at least one of the ATP III criteria for HDL-C or triglycerides [TG]. Prevalence of US-NAFLD and its associated risk factors and prevalence of hypertransaminasemia and its possible determinants were evaluated. NAFLD prevalence was 0.78. Men with steatosis compared to men without steatosis were younger (P < 0.05) with higher TG (P < 0.03), homeost…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismNonalcoholic fatty liverSex FactorSettore MED/13 - EndocrinologiaBody Mass IndexEndocrinologyNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseAtherosclerosis; Metabolic Syndrome X; Sex Factors; Humans; Lipids; Aged; Fatty Liver; Non-alcoholic Fatty Liver Disease; Body Mass Index; Italy; Logistic Models; Risk Factors; Liver; Middle Aged; Female; MaleUltrasonographyMulticentric studyMetabolic Syndrome XFatty liverGeneral MedicineArteriosclerosisLipidMiddle AgedLipidsMetabolic syndromeDiabetes and MetabolismItalyLiverAtherosclerosiFemaleHumanmedicine.medical_specialtyLogistic ModelNonalcoholic fatty liver Metabolic syndrome Lipids Multicentric studyInsulin resistanceSex FactorsDiabetes mellitusInternal medicinemedicineInternal MedicineHumansLipids; Metabolic syndrome; Multicentric study; Nonalcoholic fatty liver; Aged; Body Mass Index; Fatty Liver; Female; Humans; Italy; Lipids; Liver; Logistic Models; Male; Metabolic Syndrome X; Middle Aged; Non-alcoholic Fatty Liver Disease; Risk Factors; Sex Factors; Atherosclerosis; Endocrinology; Internal Medicine; Endocrinology Diabetes and MetabolismAgedbusiness.industryRisk Factornutritional and metabolic diseasesAmbientalemedicine.diseaseAtherosclerosisFatty LiverEndocrinologyLogistic ModelsMetabolic syndromeSteatosisbusinessBody mass index
researchProduct

Risk factors for hospital readmission of elderly patients

2012

Background: The aim of this study was to identify which factors were associated with a risk of hospital readmission within 3 months after discharge of a sample of elderly patients admitted to internal medicine and geriatric wards. Methods: Of the 1178 patients aged 65 years or more and discharged from one of the 66 wards of the 'Registry Politerapie SIMI (REPOSI)' during 2010, 766 were followed up by phone interview 3 months after discharge and were included in this analysis. Univariate and multivariate logistic regression models were used to evaluate the association of several variables with rehospitalization within 3 months from discharge. Results: Nineteen percent of patients were readmi…

MaleSettore MED/09 - Medicina InternaTime FactorsRisk factors; internal medicine; Geriatric patient; hospital admissionLogistic regressionElderly; Hospital readmission; Internal medicine and geriatric wards; Risk factorsElderlyInternal medicine and geriatric wards80 and overElderly; Hospital readmission; Internal medicine and geriatric wards; Risk factors; Aged; Aged 80 and over; Female; Geriatrics; Hospital Departments; Humans; Internal Medicine; Male; Patient Readmission; Risk Factors; Time Factors; Internal MedicineMedical diagnosisAged Aged; 80 and over Female Geriatrics Hospital Departments Humans Internal Medicine Male Patient Readmission; statistics /&/ numerical data Risk Factors Time FactorsAged 80 and overGeriatricsUnivariate analysisvascular diseaseHospital readmissionSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheAgeing; readmissionstatistics /&/ numerical dataHospital DepartmentFemaleliver diseaseHumanmedicine.medical_specialtyTime FactorHospital DepartmentsMEDLINEHospital readmission Internal medicine and geriatric wards Risk factors Elderlyelderly patientsPatient ReadmissionNOInternal MedicinemedicineHumansRegistry Politerapie SIMI (REPOSI)Adverse effectAgedreadmissionbusiness.industryRisk FactorUnivariatemedicine.diseaseComorbidityHospital readmission; elderly patients; Registry Politerapie SIMI (REPOSI); vascular disease; liver diseaseHospital readmission; Internal medicine and geriatric wards; Risk factors; Elderlyelderly; hospital readmission; risk factors; internal medicine and geriatric wardsInternal medicine and geriatric wardAgeingGeriatric patienthospital admissionRisk factorsGeriatricsEmergency medicinebusinessGeriatricEuropean Journal of Internal Medicine
researchProduct

Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: The ITA.LI.CA database

2021

BackgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort.MethodsWe analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC.ResultsMAFLD was diagnosed in the majority of patients w…

MaleSettore MED/12 - GastroenterologiaCarcinoma HepatocellularLiver Neoplasmsnonalcoholic steatohepatitis.Gastroenterologyhepatocellular carcinomadigestive system diseaseshepatocellular carcinoma; nonalcoholic steatohepatitisNon-alcoholic Fatty Liver DiseaseRisk FactorsHumansnonalcoholic steatohepatitisneoplasms
researchProduct

Reply

2015

MaleSettore MED/12 - GastroenterologiaCarotid Artery DiseaseHepatologybusiness.industryPharmacologyLipoproteins VLDLMembrane proteinNon-alcoholic Fatty Liver DiseaseMedicineFemalebusinessMembrane ProteinVldl metabolismHuman
researchProduct

Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease.

2015

The small heterodimer partner (SHP) (NR0B2) is an atypical nuclear receptor that lacks a DNA-binding domain. It interacts with and inhibits many transcription factors, affecting key metabolic processes, including bile acid, cholesterol, fatty acid, and drug metabolism. Our aim was to determine the influence of steatotic drugs and nonalcoholic fatty liver disease (NAFLD) on SHP expression and investigate the potential mechanisms. SHP was found to be repressed by steatotic drugs (valproate, doxycycline, tetracycline, and cyclosporin A) in cultured hepatic cells and the livers of different animal models of NAFLD: iatrogenic (tetracycline-treated rats), genetic (glycine N-methyltransferase-defi…

MaleTranscription GeneticThiazepinesResponse elementReceptors Cytoplasmic and NuclearBiologyMiceNon-alcoholic Fatty Liver DiseaseCyclosporin amedicineCCAAT-Enhancer-Binding Protein-alphaAnimalsHumansProtein kinase APromoter Regions GeneticTranscription factorCells CulturedPharmacologyMitogen-Activated Protein Kinase 1KinaseValproic AcidFatty liverTetracyclinemedicine.diseaseFatty LiverDoxycyclineCancer researchSmall heterodimer partnerCyclosporineMolecular MedicineSignal transductionSignal TransductionMolecular pharmacology
researchProduct